es | en | pt | fr
    • Presentación
    • Países
    • Instituciones
    • Participa
        JavaScript is disabled for your browser. Some features of this site may not work without it.
        Ver ítem 
        •   Inicio
        • Colombia
        • Universidades
        • Universidad Jorge Tadeo Lozano (Colombia)
        • Ver ítem
        •   Inicio
        • Colombia
        • Universidades
        • Universidad Jorge Tadeo Lozano (Colombia)
        • Ver ítem

        Inhibition of cytokine signaling by ruxolitinib and implications for COVID19 treatment

        Registro en:
        1521-6616
        https://doi.org/10.1016/j.clim.2020.108517
        http://hdl.handle.net/20.500.12010/10371
        http://expeditiorepositorio.utadeo.edu.co
        https://doi.org/10.1016/j.clim.2020.108517
        http://repositorioslatinoamericanos.uchile.cl/handle/2250/3507306
        Autor
        Yeleswaram, Swamy
        Smith, Paul
        Burn, Timothy
        Juvekar, Ashish
        Li, Yanlong
        Squier, Peg
        Langmuir, Peter
        Institución
        • Universidad Jorge Tadeo Lozano (Colombia)
        Resumen
        Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma levels of pro-inflammatory cytokines, which can result in cytokine storm, followed by massive immune cell infiltration into the lungs leading to alveolar damage, decreased lung function, and rapid progression to death. As many of the elevated cytokines signal through Janus kinase (JAK)1/JAK2, inhibition of these pathways with ruxolitinib has the potential to mitigate the COVID-19–associated cytokine storm and reduce mortality. This is supported by preclinical and clinical data from other diseases with hyperinflammatory states, where ruxolitinib has been shown to reduce cytokine levels and improve outcomes. The urgent need for treatments for patients with severe disease support expedited investigation of ruxolitinib for patients with COVID-19.
        Materias
        Cytokine storm
        COVID-19
        Ruxolitinib
        Janus kinase
        Coronavirus

        Mostrar el registro completo del ítem


        Red de Repositorios Latinoamericanos
        + de 8.000.000 publicaciones disponibles
        500 instituciones participantes
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Ingreso Administradores
        Colecciones destacadas
        • Tesis latinoamericanas
        • Tesis argentinas
        • Tesis chilenas
        • Tesis peruanas
        Nuevas incorporaciones
        • Argentina
        • Brasil
        • Colombia
        • México
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Red de Repositorios Latinoamericanos | 2006-2018
         

        EXPLORAR POR

        Instituciones
        Fecha2011 - 20202001 - 20101951 - 20001901 - 19501800 - 1900

        Explorar en Red de Repositorios

        Países >
        Tipo de documento >
        Fecha de publicación >
        Instituciones >

        Red de Repositorios Latinoamericanos
        + de 8.000.000 publicaciones disponibles
        500 instituciones participantes
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Ingreso Administradores
        Colecciones destacadas
        • Tesis latinoamericanas
        • Tesis argentinas
        • Tesis chilenas
        • Tesis peruanas
        Nuevas incorporaciones
        • Argentina
        • Brasil
        • Colombia
        • México
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Red de Repositorios Latinoamericanos | 2006-2018